Alkermes, INC.

​Pharmaceutical manufacturing and biopharmaceutical company.

Based in MA

🤖

AI Overview

With $1.4M in lobbying spend across 28 quarterly filings, Alkermes, INC. is a significant lobbying presence.

$1.4M
Total Lobbying Spend
28
Quarterly Filings
1
Lobbying Firms Used
9
Individual Lobbyists

Spending by Year

YearLobbying Spend
2019$50K
2020$200K
2021$300K
2022$250K
2023$200K
2024$200K
2025$240K

Lobbying Firms

TODD STRATEGY GROUP

What They Lobby For

  • Prescription drug pricing.
  • Criminal justice bill introduction.
  • Prescription drug pricing. C.R.8337: Continuing Appropriations Act, 2021.
  • Appropriations related to SAMHSA grant services.
  • Prescription drug pricing. H.R.5376 - Build Back Better Act. H.R.3684 - Infrastructure Investment and Jobs Act.
  • Prescription drug pricing. H.R.5376 - Build Back Better Act.
  • Prescription drug pricing. S.3799 - Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT) Pandemics Act. Awareness of outcomes data and the need for training on all medication assisted treatment. H.R.7667/S.4348 - Prescription Drug User Fee Agreement Reauthorization. H.R.5376 - Inflation Reduction Act of 2022.
  • Prescription drug pricing. Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022.
  • Prescription drug pricing, including MDRP Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022. Medicaid drug rebate program.
  • Prescription drug pricing, including MDRP. Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022. Medicaid drug rebate program.

Related Investigations

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.